Cite
HARVARD Citation
Bear, H. et al. (n.d.). Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet oncology. 16 (9), pp. 1037-1048. [Online].